A Research Roadmap for Complementary and Alternative Medicine - What We Need to Know by 2020 by Fischer, Felix et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2014
A Research Roadmap for Complementary and Alternative Medicine - What
We Need to Know by 2020
Fischer, Felix; Lewith, George; Witt, Claudia M; Linde, Klaus; Ammon, Klaus; Cardini, Francesco;
Falkenberg, Torkel; Fønnebø, Vinjar; Johannessen, Helle; Reiter, Bettina; Uehleke, Bernhard;
Brinkhaus, Benno
Abstract: Unspecified
DOI: 10.1159/000360744
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-103165
Published Version
Originally published at:
Fischer, Felix; Lewith, George; Witt, Claudia M; Linde, Klaus; Ammon, Klaus; Cardini, Francesco;
Falkenberg, Torkel; Fønnebø, Vinjar; Johannessen, Helle; Reiter, Bettina; Uehleke, Bernhard; Brinkhaus,
Benno (2014). A Research Roadmap for Complementary and Alternative Medicine - What We Need to
Know by 2020. Forschende Komplementärmedizin, 21(2):e1-e16. DOI: 10.1159/000360744
Original Article · Originalarbeit – E-Only Publication
Forsch Komplementmed 2014;21:e1–e16 Published online: March 24, 2014
DOI: 10.1159/000360744
Felix Fischer, PhD
Institute for Social Medicine, Epidemiology and Health Economics
Charité – University Medical Center
Luisenstraße 57, 10098 Berlin, Germany
felix.fischer@charite.de
© 2014 S. Karger GmbH, Freiburg
1661-4119/14/0212-••••$39.50/0
Accessible online at: 
www.karger.com/fok
Fax +49 761 4 52 07 14
Information@Karger.com
www.karger.com
A Research Roadmap for Complementary and  
Alternative Medicine – What We Need to Know by 2020
Felix Fischera  George Lewithb  Claudia M. Witta,c  Klaus Linded  Klaus von Ammone  
Francesco Cardinif  Torkel Falkenbergg,h  Vinjar Fønnebøi  Helle Johannessenj  
Bettina Reiterk  Bernhard Uehlekel  Wolfgang Weidenhammerm  Benno Brinkhausa
a Institute for Social Medicine, Epidemiology, and Health Economics, Charité University Medical Center, Berlin, Germany
b Complementary and Integrated Medicine Research Unit, University of Southampton, UK
c  Center for Integrative Medicine, School of Medicine, University of Maryland, Baltimore, MD, USA
d Institute of General Practice, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
e Institute of Complementary Medicine (KIKOM), University of Bern, Switzerland 
f Healthcare and Social Agency of Emilia Romagna Region, Bologna, Italy
g Research Unit for Integrative Healthcare Research, Karolinska Institute, Stockholm, 
h IC – The Integrative Care Science Center, Järna, Sweden
i  National Research Center on Complementary and Alternative Medicine (NAFKAM), University of Tromsø, Norway
j Institute of Public Health, Research Unit Health, Man and Society, University of Southern Denmark, Odense, Denmark
k International Academy for Holistic Medicine, Vienna, Austria
l  Institute of Complementary Medicine, Department of Internal Medicine, University Hospital Zurich, Switzerland
m Competence Centre for Complementary Medicine and Naturopathy, Klinikum rechts der Isar, Technische Universität München, 
Munich, Germany
and private sectors. One major issue in the European 
research agenda is the demographic change and its im-
pact on health care. Our vision for 2020 is that there is 
an evidence base that enables European citizens to 
make informed decisions about CAM, both positive and 
negative. This roadmap proposes a strategic research 
agenda for the field of CAM designed to address future 
European health care challenges. This roadmap is based 
on the results of CAMbrella’s several work packages, lit-
erature reviews and expert discussions including a con-
sensus meeting. Methods: We first conducted a system-
atic literature review on key issues in clinical and 
epidemiological research in CAM to identify the general 
concepts, methods and the strengths and weaknesses 
of current CAM research. These findings were discussed 
in a workshop (Castellaro, Italy, September 7–9th 2011) 
with international CAM experts and strategic and meth-
odological recommendations were defined in order to 
improve the rigor and relevance of CAM research. These 
recommendations provide the basis for the research 
roadmap, which was subsequently discussed in a con-
sensus conference (Järna, Sweden, May 9–11th 2012) 
with all CAMbrella members and the CAMbrella advi-
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Summary
Background: The CAMbrella coordination action was 
funded within the Framework Programme 7. Its aim is to 
provide a research roadmap for clinical and epidemio-
logical research for complementary and alternative 
medicine (CAM) that is appropriate for the health needs 
of European citizens and acceptable to their national re-
search institutes and healthcare providers in both public 
A short version of work package 7 work and results including the 
CAMbrella research roadmap has been published recently in Fischer 
HF, Lewith G, Witt CM, Linde K, von Ammon K, Cardini F, Falken-
berg T, Fønnebø V, Johannessen H, Reiter B, Uehleke B, Weidenham-
mer W, Brinkhaus B: High prevalence but limited evidence in comple-
mentary and alternative medicine: guidelines for future research. BMC 
Complement Altern Med 2014;14:46.
Other major findings  of the EU project CAMbrellawww.karger.com/Journal/Issue/257354
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ing quantitative and qualitative methods should be con-
sidered to enable us to secure the greatest density of 
knowledge possible. Stakeholders, such as citizens, pa-
tients and providers, should be involved in every stage 
of developing the specific and relevant research ques-
tions, study design and the assurance of real-world rel-
evance for the research. Furthermore, structural and 
sufficient financial support for research into CAM is 
needed to strengthen CAM research capacity if we wish 
to understand why it remains so popular within the EU. 
In order to consider employing CAM as part of the solu-
tion to the health care, health creation and self-care 
challenges we face by 2020, it is vital to obtain a robust 
picture of CAM use and reliable information about its 
cost, safety and effectiveness in real-world settings. We 
need to consider the availability, accessibility and af-
fordability of CAM. We need to engage in research ex-
cellence and utilise comparative effectiveness ap-
proaches and mixed methods to obtain this data. Our 
recommendations are both strategic and methodologi-
cal. They are presented for the consideration of re-
searchers and funders while being designed to answer 
the important and implicit questions posed by EU citi-
zens currently using CAM in apparently increasing num-
bers. We propose that the EU actively supports an EU-
wide strategic approach that facilitates the development 
of CAM research. This could be achieved in the first in-
stance through funding a European CAM coordinating 
research office dedicated to foster systematic communi-
cation between EU governments, public, charitable and 
industry funders as well as researchers, citizens and 
other stakeholders. The aim of this office would be to 
coordinate research strategy developments and re-
search funding opportunities, as well as to document 
and disseminate international research activities in this 
field. With the aim to develop sustainability as second 
step, a European Centre for CAM should be established 
that takes over the monitoring and further development 
of a coordinated research strategy for CAM, as well as it 
should have funds that can be awarded to foster high 
quality and robust independent research with a focus 
on citizens health needs and pan-European collabora-
tion. We wish to establish a solid funding for CAM re-
search to adequately inform health care and health crea-
tion decision-making throughout the EU. This centre 
would ensure that our vision of a common, strategic 
and scientifically rigorous approach to CAM research 
becomes our legacy and Europe’s reality. We are confi-
dent that our recommendations will serve these essen-
tial goals for EU citizens.
sory board. The roadmap was revised after this discus-
sion in CAMbrella Work Package (WP) 7 and finally ap-
proved by CAMbrella’s scientific steering committee on 
September 26th 2012. Results: Our main findings show 
that CAM is very heterogenous in terms of definitions 
and legal regulations between the European countries. 
In addition, citizens’ needs and attitudes towards CAM 
as well as the use and provision of CAM differ signifi-
cantly between countries. In terms of research method-
ology, there was consensus that CAM researchers 
should make use of all the commonly accepted scien-
tific research methods and employ those with utmost 
diligence combined in a mixed methods framework. 
Conclusions: We propose 6 core areas of research that 
should be investigated to achieve a robust knowledge 
base and to allow stakeholders to make informed deci-
sions. These are:
Research into the prevalence of CAM in Europe: Re-
views show that we do not know enough about the cir-
cumstances in which CAM is used by Europeans. To en-
able a common European strategic approach, a clear 
picture of current use is of the utmost importance. 
Research into differences regarding citizens’ attitudes 
and needs towards CAM: Citizens are the driver for CAM 
utilization. Their needs and views on CAM are a key pri-
ority, and their interests must be investigated and ad-
dressed in future CAM research.
Research into safety of CAM: Safety is a key issue for 
European citizens. CAM is considered safe, but reliable 
data is scarce although urgently needed in order to as-
sess the risk and cost-benefit ratio of CAM. 
Research into the comparative effectiveness of CAM: 
Everybody needs to know in what situation CAM is a 
reasonable choice. Therefore, we recommend a clear 
emphasis on concurrent evaluation of the overall effec-
tiveness of CAM as an additional or alternative treat-
ment strategy in real-world settings. 
Research into effects of context and meaning: The im-
pact of effects of context and meaning on the outcome 
of CAM treatments must be investigated; it is likely that 
they are significant. 
Research into different models of CAM health care inte-
gration: There are different models of CAM being inte-
grated into conventional medicine throughout Europe, 
each with their respective strengths and limitations. 
These models should be described and concurrently 
evaluated; innovative models of CAM provision in 
health care systems should be one focus for CAM re-
search.
We also propose a methodological framework for CAM 
research. We consider that a framework of mixed meth-
odological approaches is likely to yield the most useful 
information. In this model, all available research strate-
gies including comparative effectiveness research utilis-
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Verfahren. Es ist Konsens, dass CAM-Verfahren im Rah-
men der bekannten und akzeptierten wissenschaftlichen 
Forschungsmethoden erforscht und dabei verschiedene 
Forschungsperspektiven berücksichtigt werden sollen. 
Schlussfolgerungen: Wir schlagen 6 zentrale For-
schungsgebiete vor. Diese erscheinen uns als maßgeb-
lich für den Aufbau einer Wissensbasis zur Förderung 
informierter Entscheidungen. Diese sind:
Prävalenz: Bisher gibt es zu wenige Daten über die Situa-
tionen, in denen CAM in Europa genutzt und eingesetzt 
wird. Um die Umsetzung einer europaweiten Forschungs-
strategie zu ermöglichen, muss die Datenlage über die 
Nutzung von CAM dringend verbessert werden.
Einstellungen und Bedürfnisse: Die Bürger Europas sind 
der Hauptmotor für den Einsatz von CAM. Ihre Bedürf-
nisse und Einstellungen spielen eine entscheidende 
Rolle und müssen daher erforscht und berücksichtigt 
werden.
Sicherheit: Die Sicherheit komplementär- und alterna-
tivmedizinischer Verfahren ist ein Kernanliegen. CAM 
wird zwar häufig als sicher angesehen, aber für eine Be-
wertung des Verhältnisses von Kosten und Nutzen muss 
die Datenlage verbessert werden. 
Wirksamkeit: Jeder sollte wissen können, ob und wann 
komplementär- und alternativmedizinische Verfahren 
eine vernünftige Wahl sind. Darum empfehlen wir einen 
klaren Fokus auf klinische Studien des Behandlungs-
alltags, die den Gesamtnutzen komplementär- und al-
ternativmedizinischer Verfahren als zusätzliche oder 
 alternative Behandlungsmethode erforschen. 
Kontext: Der Einfluss von Kontexteffekten wie Erwar-
tungen muss weiter erforscht werden; wir halten sie für 
bedeutsam. 
Modelle der Integration: Die verschiedenen Modelle der 
Einbindung von CAM in die Gesundheitssysteme mit 
ihren spezifischen Stärken und Schwächen sollten zu-
nächst beschrieben und evaluiert werden. Weiterhin 
sollten neue, innovative Ansätze der Integration er-
forscht werden.
Unser Vorschlag bezieht sich auch auf einen methodi-
schen Rahmen. Das Höchstmaß an Wissen wird unserer 
Meinung nach mit einem «mixed methods»-Ansatz er-
reicht, in dem zur Beantwortung der Forschungsfrage 
unterschiedliche Methoden kombiniert werden. Stake-
holder wie z.B. Bürger, Patienten und CAM-Anbieter 
sollten in allen Phasen der Studienplanung involviert 
werden, um die Relevanz der Forschungsfrage und 
Durchführbarkeit der Studie zu verbessern. Außerdem 
muss es eine strukturelle und ausreichende Förderung 
solcher Forschung geben, sowohl auf Projektebene als 
auch als Förderung einzelner Wissenschaftler. Eine sol-
che Stärkung der wissenschaftlichen Infrastruktur ist 
notwendig, wenn wir verstehen wollen, warum CAM so 
populär in Europa ist.
Schlüsselwörter
Klinische Forschung · Epidemiologische Forschung · 
Forschungsmethodik · 
Komplementäre und alternative Medizin · 
Konsensusprozess · Forschungsprioritäten
Zusammenfassung
Hintergrund: CAMbrella wurde als Koordinierungspro-
jekt im Rahmen des 7. Rahmenprogramms für For-
schung und technologische Entwicklung der Europäi-
schen Kommission gefördert. Aufgabe des Projekts war 
es, eine «Roadmap» für künftige klinische und epide-
miologische Forschung auf dem Feld der Komplemen-
tär- und Alternativmedizin (CAM) zu entwickeln, die den 
Bedürfnissen der Bevölkerung Europas Rechnung trägt 
und sowohl nationalen Forschungseinrichtungen als 
auch privaten und öffentlichen Anbietern von Gesund-
heitsdienstleistungen entgegenkommt. Eine der großen 
Herausforderungen für die Wissenschaft in Europa ist 
der demografische Wandel und seine Folgen für die Ge-
sundheitssysteme. Unser Ziel für das Jahr 2020 ist es, 
eine Wissensbasis zu schaffen, die es den Bürgern Euro-
pas ermöglicht, informierte Entscheidungen hinsicht-
lich komplementär- und alternativmedizinischer Verfah-
ren zu treffen. Mit dieser Roadmap schlagen wir eine 
Forschungsstrategie vor, die diesen zukünftigen Her-
ausforderungen gerecht wird. Diese Strategie beruht 
auf den Ergebnissen der einzelnen Arbeitsgruppen des 
CAMbrella-Projekts, systematischen Literaturübersich-
ten und Expertendiskussionen einschließlich einer Kon-
sensuskonferenz. Methoden: Als erster Schritt wurde 
ein systematischer Literaturüberblick erarbeitet, in dem 
allgemeine Konzepte, Methoden sowie Stärken und 
Schwächen der bisherigen komplementärmedizini-
schen Forschung identifiziert wurden. Die hieraus 
 gewonnenen zentralen Ergebnisse wurden mit inter-
national renommierten Experten im Rahmen eines 
Workshops (Castellaro, Italien, 7.–9. September 2011) 
diskutiert und Empfehlungen erarbeitet, die die Qualität 
und Relevanz von komplementärmedizinischer For-
schung erhöhen sollen. Diese Empfehlungen stellen die 
Basis der hier vorgeschlagenen Forschungsstrategie 
dar, die in der Folge im Rahmen einer Konsensuskonfe-
renz (Järna, Schweden, 9.–11. Mai 2012) mit allen Mit-
gliedern des CAMbrella-Konsortiums einschließlich des 
Beirates abgestimmt wurde. Die Roadmap wurde in der 
Folge im CAMbrella Work Package (WP) 7 überarbeitet 
und schließlich durch CAMbrellas Leitungsgremium am 
26. September 2012 freigegeben. Ergebnisse: Sowohl 
Definition als auch rechtlicher Status von CAM-Verfah-
ren unterscheiden sich stark zwischen den Ländern Eu-
ropas. Dies gilt auch für die Bedürfnisse und Einstellun-
gen der in Europa lebenden Menschen bezüglich dieser 
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derern, Wissenschaftlern und Bürgern fördert. Ein Ziel 
dieser Institution könnte sein, strategische Entwicklun-
gen und Forschungsfördermöglichkeiten zu koordinie-
ren, zu dokumentieren und zu verbreiten. Als zweiter 
Schritt könnte ein European Centre for CAM gegründet 
werden, dass die Umsetzung und Weiterentwicklung ei-
ner europäischen Forschungsstrategie verfolgt. Dieses 
Zentrum sollte über Mittel verfügen, um besonders rele-
vante Forschung, die ihr Augenmerk auf die Bedürfnisse 
der Bürger richtet, in länderübergreifenden Projekten zu 
fördern. Wir halten eine solche solide Finanzierungs-
grundlage für unerlässlich, um individuelle und politi-
sche Entscheidungsprozesse hinsichtlich CAM unterstüt-
zen zu können. Eine solche Institution könnte sicherstellen, 
dass eine europäische strategisch ausgerichtete und wis-
senschaftlich belastbare CAM-Forschung auf der Basis 
der unterbreiteten Vorschläge umgesetzt werden kann.
Damit CAM einen Teil zur Lösung von Herausforderun-
gen im Bereich Gesundheit leisten kann, mit denen wir 
bis zum Jahr 2020 konfrontiert sein werden, ist ein ge-
nauer Überblick über die Häufigkeit der Nutzung ebenso 
notwendig wie valide Informationen zu Wirksamkeit, Si-
cherheit und Kosten. Die Verfügbarkeit, Erreichbarkeit 
und Bezahlbarkeit von CAM muss berücksichtigt werden. 
Wissenschaftliche Exzellenz muss gefördert werden. Un-
sere Empfehlungen sind sowohl strategischer als auch 
methodologischer Natur. Sie sollen sowohl von For-
schern als auch Förderern berücksichtigt werden und 
wurden entwickelt, um die wichtigen Fragen von EU-Bür-
gern zu beantworten, unter denen die Anzahl der CAM-
Nutzer weiter steigt. Die EU sollte eine europaweite For-
schungsstrategie unterstützen und könnte das zunächst 
durch die Gründung eines Europäischen CAM-Koordinie-
rungsbüros erreichen, das die Kommunikation zwischen 
Regierungen, öffentlichen und privaten Forschungsför-
Preface
The use of complementary and alternative medicine (CAM) 
including practices such as acupuncture, anthroposophic medi-
cine, aromatherapy, herbal medicine, homeopathy, kinesiology, 
massage, naturopathy, shiatsu, and yoga has increased in West-
ern industrialised nations over the last 25 years [1–3]. The 
WHO Global Atlas of Traditional, Complementary and Alter-
native Medicine [4] concludes that CAM is highly prevalent 
within Europe. However, the report was unable to arrive at a 
clear picture of CAM use across the whole EU as the only reli-
able evidence available came from just a few EU member 
states. Furthermore, there has been little interest from the 
pharmaceutical industry or national publicly funded research 
organizations within the EU in understanding more about this 
field. Consequently, European research in the field of CAM is 
limited and our knowledge about CAM is very poor; for in-
stance in the UK 0.0085% of national medical research funds 
are spent on CAM research while over 10% of the UK popula-
tion uses CAM each year and approximately 50% are lifetime 
users [5]. In contrast, in the USA CAM research has been well 
funded over the last 2 decades with more than USD 120 Mil-
lion annually through National Institutes of Health (NIH) 
funds from the National Center for Complementary and Al-
ternative Medicine (NCCAM; www.nccam.nih.gov).
There is considerable heterogeneity within CAM in the 
EU; this encompasses the terms, definitions, legislation, and 
providers of CAM. Physicians and non-medical providers pro-
vide CAM in a variety of settings. These differences have ham-
pered the development of a pan-European strategy for CAM 
research in the past.
There are major health care challenges in all European 
countries as the demographics change. CAM is frequently em-
ployed in the management of chronic long-term conditions, 
health promotion and illness prevention, so evidence-based 
practice is vital to future health planning. This research road-
map describes a strategic approach to CAM research for the 
period 2012–2020 and beyond. The overall aim is to provide 
the EU and its citizens with more valuable scientific informa-
tion to enable them to build the evidence for thoughtful stake-
holder decisions about CAM treatments. This roadmap deals 
with both epidemiological and clinical research and suggests 
the implementation of appropriate research methods. It is 
 important to mention that although basic research is an im-
portant field within CAM, it was excluded a priori from 
CAMbrella as part of this roadmap.
This document was approved by the CAMbrella group on 
September 26th 2012, representing members from the follow-
ing European countries: Austria, Denmark, France, Germany, 
Hungary, Italy, Norway, Romania, Spain, Sweden, Switzerland, 
and UK. The CAMbrella Scientific Steering Committee ap-
proved the final version of this CAM research roadmap.
Introduction
The increasing prevalence of antibiotic resistance, mental 
health disorders and various chronic diseases are just some ex-
amples of health issues which will become even more relevant 
in the very near future for Europe. Europe will go through 
major demographic changes with an increasing elderly popu-
lation. Obviously, such an increase challenges almost every 
aspect of our society, but this is especially true in the field of 
health care. With an older population we will most certainly 
need to deal with an increase in multi-morbidity involving a 
range of chronic diseases, such as arthritis, cardiovascular dis-
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tive Medicine Assessment in the Cancer Field’ (2002–2005). 
CAMbrella is within the 7th Framework Programme, and the 
EU simultaneously funded research into traditional Chinese 
medicine (TCM) (GP-TCM, TCM-Cancer, TCM-VASC), Ti-
betan medicine (TIBETAN) and African traditional health 
(MUTHI, BRIDGING GAPS).
In contrast to the recent research programmes, the main as-
pect of the current research programmes is a shift towards a 
more general and common strategic approach to important 
and relevant issues within Europe. One of the major issues is 
the demographic change and its impact on health care. For ex-
ample, on November 9th 2011, the EU commission adopted a 
legislative proposal for the 3rd multi-annual programme 
Health for Growth (2014–2020). It focuses on 4 specific 
objectives:
– To address shortages of resources and to facilitate uptake of 
innovation in health care in order to contribute to innova-
tive and sustainable health systems.
– To increase access to medical expertise, health care quality 
and patient safety in order to generally improve health care 
for EU citizens.
– To address the key risk factors by best-practice prevention, 
in order to prevent diseases and promote good health. 
– To develop common approaches for health emergencies.
Similarly, the European Innovation Partnership on Active 
and Healthy Ageing has been established recently. The pro-
gramme is oriented towards its headline target by 2020: in-
creasing the number of healthy life years (HLYs) by 2 in the 
EU on average. The main objectives are:
– To address prevention, early diagnosis, screening and treat-
ment of ageing-related chronic diseases, such as Alzhei-
mer’s disease, diabetes, cancer or Parkinson’s disease.
– To develop a more integrated approach to care delivery to 
improve cost-effectiveness and sustainability of health 
systems.
– To enable older people for a more independent and active 
life.
CAM is already seen by many patients as a treatment strat-
egy for chronic diseases, disease prevention and health man-
agement; it would therefore seem particularly relevant to the 2 
EU programmes mentioned above. CAM appears to enable 
self-care and the co-creation of individual health – issues that 
we wish to understand and investigate further. This roadmap 
will build the foundations for a common European research 
approach for CAM research. 
CAMbrella and Its Aims
Established under the 7th Framework Programme, 
CAMbrella is a coordination action aiming to foster a network 
for EU CAM research. CAMbrella was funded to provide an 
overview of various aspects of CAM within the EU, to identify 
the needs of the various stakeholders in this field and to analyse 
how this information might best be delivered in a thoughtful 
and pragmatic manner. One objective of this project is to de-
eases, chronic obstructive pulmonary disease (COPD), diabe-
tes and some cancers. This will challenge the scientific, person-
al and financial facilities of every health care system in Europe. 
A strategy that allows us to manage these changes is needed in 
order to serve the needs of European citizens. 
CAM
European citizens use CAM for treatment of chronic condi-
tions, but also for health maintenance, health literacy, self-em-
powerment and self-care and illness prevention. Large num-
bers of European citizens are using CAM; approximately 40% 
of patients with some common cancers, such as breast and 
prostate cancer, seek CAM during their courses of illness. 
Based on surveys in both the UK and Germany it would ap-
pear that between 10% and more than 50% of the population 
use CAM each year. These demographics call for a structured 
and thoughtful investment in CAM research to provide our 
EU citizens with evidence they need to make clear decisions 
about their CAM use.
The drivers for CAM use are many and varied. Individual 
choice is undoubtedly an important trigger for CAM use. Citi-
zens appear to make this choice because they claim that there 
are fewer side effects when using CAM and these treatments 
are considered to be safe and natural. This assumption needs 
to be investigated and challenged. CAM users often express 
the view that these approaches fit their enablement/empower-
ment process because they can actively participate in the proc-
ess of healing or coping with their illness.
In a changing society, where people want to have more con-
trol over their health and health treatments and where the 
numbers of multimorbid patients are increasing, these diverse 
drivers for CAM use are likely to become more relevant.
CAM has been defined in various ways over decades in dif-
ferent parts of the world. In order to develop a pan-European 
relevant definition of CAM, the authoritative World Health 
Organization (WHO) definition of CAM was slightly revised 
to accommodate European traditional medicine systems and 
the fact that some systems and modalities may be used today 
within conventional health care: 
‘Complementary and Alternative Medicine (CAM) utilised 
by European citizens represents a variety of different medical 
systems and therapies based on the knowledge, skills and prac-
tices derived from theories, philosophies and experiences used 
to maintain and improve health, as well as to prevent, diagnose, 
relieve or treat physical and mental illnesses. CAM has been 
mainly used outside conventional health care, but in some 
countries certain treatments are being adopted or adapted by 
conventional health care.’ (CAMbrella Work Package 1).
CAM within the EU
There have been some efforts by the European Union to 
gather knowledge in the field of CAM, e.g., the ‘COST B4’ 
project on unconventional medicine in Europe (1993–1995) 
and the ‘Concerted Action for Complementary and Alterna-
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directives; 3. Several EU directives and other legal and infor-
mal documents have an indirect but important influence on 
how patients, practitioners and researchers can relate to CAM 
in Europe.
Although diversity in health care regulation enables a wid-
er choice of options with regard to CAM in health care, the 
same diversity seriously hampers any efforts to establish EU-
wide conditions for both treatment and research.
WP 3 – citizens: Many citizens in Europe have positive at-
titudes to CAM, and although their attitudes and needs have 
not been consistently researched across all European coun-
tries, some salient and consistent observations emerge: a) Citi-
zens in Europe wish to have access to increased and diverse 
CAM provision; b) Citizens in Europe need easily accessible 
and trustworthy information regarding CAM, CAM effective-
ness and CAM safety; c) Citizens in Europe require the trans-
parent regulation of CAM products, practitioners and the 
training of those who practice CAM.
The attitudes and needs of citizens in Europe concerning 
CAM have been researched in just 18 of 39 European coun-
tries; substantial research-based knowledge is primarily avail-
able from the UK, while some – but not extensive – knowledge 
is available from a few other European countries. This suggests 
that more research in this field is needed.
WP 4 – patients: We are unsure about the exact extent of 
CAM use within the EU. The data available from the WP4 sys-
tematic review is inconclusive and of very variable quality. 
Many of the studies are of poor methodological quality. There 
is reliable data in a few countries, but in the majority of the 27 
EU states we have no data. A questionnaire-based tool is 
needed to measure the prevalence of core CAM practices and 
to obtain reliable population-based data. The existing and pi-
loted questionnaire ICAMQ will require major revision be-
fore it can be widely utilised for this purpose.
WP 5 – providers: CAM provision in Europe comprises 
health care practitioners and physicians with different healing 
attitudes, medical background, training, certification and prac-
tice. Public available data on CAM provision is limited, and 
scientific publications investigating this field are almost com-
pletely lacking. Our main conclusions are: a) CAM provision 
in Europe requires the transparent harmonisation of CAM 
training, medical education and certification; b) CAM provi-
sion in Europe requires the standards of the regulation and 
registration bodies for both, therapists and products, to be 
open to the public; c) CAM provision in Europe appears to 
have been a neglected field of research. Publically funded re-
search evidence is mainly available from Denmark, Germany, 
Norway, Switzerland and UK. This suggests that more research 
is needed in this field throughout the EU and associated 
countries.
WP 6 – global perspective: From an international perspec-
tive including the experience from China, USA, Asia and Aus-
tralia, it seems that a broad range of mixed methods research 
strategies should be used to investigate CAM within the EU. 
velop a roadmap for future European research in CAM that is 
appropriate for the health needs of European citizens and ac-
ceptable to their public and private national research institutes 
and health care providers. In order to achieve this, major EU-
based CAM research groups were identified and brought to-
gether to allow the development of a structured and coopera-
tive collaboration. CAMbrella aimed to identify the major 
international research stakeholders and seek their advice and 
cooperation as well as to link to stakeholders representing 
CAM users, medical and non-medical providers and producers.
Prior to the project, a number of requirements were identi-
fied, which are crucial to enable meaningful and reliable com-
parisons within Europe in this neglected health care domain. 
These requirements include the need for definitions for CAM 
and a clearer picture of CAM in the various European coun-
tries with respect to the expectations and requirements of the 
populations seeking CAM treatment. The specific aims of 
CAMbrella and the associated work packages (WP) can be 
summarised as to
– develop a consensus-based pan-European CAM definition 
(WP 1);
– review the current legal status of CAM in Europe (WP 2);
– explore the needs and attitudes of the EU citizens with re-
spect to CAM (WP 3); 
– evaluate patient demand for CAM and its prevalence in 
Europe (WP 4);
– explore the providers’ perspectives of CAM treatment in 
Europe (WP 5); 
– evaluate the global perspective and strategy for CAM re-
search (WP 6);
– propose an appropriate research roadmap for CAM in the 
EU (WP 7);
– disseminate and communicate the outcomes of 
CAMbrella; 
– foster a sustainable, high quality collaboration of European 
CAM researchers (WP 8).
The results from WP 1–6 were fed into the development of 
the research roadmap. Their key messages are as follows.
WP 1 – terminology: The work package proposes a broad 
definition of CAM: ‘Complementary and Alternative Medi-
cine (CAM) utilised by European citizens represents a variety 
of different medical systems and therapies based on the knowl-
edge, skills and practices derived from theories, philosophies 
and experiences used to maintain and improve health, as well 
as to prevent, diagnose, relieve or treat physical and mental 
illnesses. CAM has been mainly used outside conventional 
health care, but in some countries certain treatments are being 
adopted or adapted by conventional health care.’
WP 2 – regulation: The situation with regard to CAM regu-
lation can be summarised in 3 key points: 1. There is no com-
mon approach to the regulation of CAM practice in Europe. 
All 39 countries that were studied ‘do it their own way.’; 
2. Market authorizations of herbal and homeopathic products 
are regulated similarly in each country in accordance with EU 
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internationally renowned experts in the field of CAM re-
search. Within this workshop recommendations for further 
research were developed as the first draft of the roadmap. 
These recommendations suggest the early involvement of rel-
evant stakeholders when identifying research questions and 
planning research projects in the field of CAM. They recom-
mend that research should be conducted within a real-world 
setting to foster evidence for safety and costs as well as to es-
tablish knowledge on the range of benefits to users. The most 
relevant outcomes of CAM treatments need to be identified as 
well as the public health, health education and clinical situa-
tions in which CAM could be appropriate. In addition, use of a 
broad variety of research methods is recommended, and dif-
ferent types of evidence should be taken into consideration. 
This includes the need for research training and collaboration 
with users, providers and other relevant stakeholders. Harmo-
nised prevalence research for EU CAM use is urgently needed 
and should be one of the first steps toward a broader and more 
detailed picture of the state of CAM practice in Europe. Safety 
is a major issue because it is fundamental to the interests of 
users and providers. Additionally, mechanisms of action are 
still poorly understood for most CAM modalities. Given the 
effects experienced by users and providers of CAM, research 
should include exploration into the nature and impact of those 
effects. Mixed research methods rather than sole reliance on 
randomised controlled trials are more likely to provide a 
broad understanding of CAM, its effects and potential appli-
cability in health care. A Europe-wide approach to research 
should take advantage of the diversity of CAM throughout 
Europe and allow comparisons between different models of 
health system integration with regard to safety, efficacy, effec-
tiveness and the health economic outcomes of CAM 
treatments. 
Based on the results from the literature review and the Cas-
tellaro workshop, this roadmap has been developed to estab-
lish a strategic guide for future CAM research. We aimed to 
create a roadmap that is appropriate for the health needs of 
European citizens and acceptable to their public and private 
national research institutes and health care providers. 
CAM Research Roadmap
Vision
Our vision for the year 2020 is that research into CAM will 
provide a broad but relevant and comprehensive evidence 
base that enables European citizens and health care providers 
to come to informed decisions about CAM utilisation for both 
the individual and society as a whole. We believe that knowl-
edge regarding safety, effectiveness and cost-effectiveness of 
CAM therapies is crucial to enable those decisions. Further-
more, these decisions need an overall research strategy for 
CAM that is evidence-based and grounded in clinical practice. 
We note that CAM is frequently utilised for self-care and per-
CAM research strategy for Europe should be based on con-
sensus of the relevant stakeholders, users, providers, research-
ers and health policy makers; it should be related to national 
or regional public health needs, disease burden and the preva-
lence of particular modalities. WP6 suggests the formation of a 
centralised EU CAM centre with the responsibility to opera-
tionalise the CAMbrella recommendations in collaboration 
with selected EU member states and appropriate (worldwide) 
CAM academic institutions. This will enable an evidence- 
informed health sector reform with appropriate CAM inter-
ventions in the EU.
A coordinated research action within the EU will face 
enormous diversity in the field of CAM and its legal regula-
tion. It must address the lack of comprehensive basic knowl-
edge about attitudes towards CAM as well as its use and provi-
sion. It would be wise to learn from international experience.
Work Package 7 of CAMbrella
The overall aim of CAMbrella WP 7 is to identify consensus- 
based research strategies for CAM research and to develop a 
general research map for future clinical and epidemiological 
research in the field of CAM. In order to describe the chal-
lenges that have occurred in CAM research, we analysed 
the research methods already used for clinical and epidemio-
logical CAM research by conducting a systematic literature 
review. We also reviewed the research methods used in the 
studies examined within WP 3, 4 and 5. Finally, we proposed 
strategies and methods to overcome the shortcomings in prev-
alence research and research into citizens’ needs.
We identified 3,279 references derived from 7 electronic da-
tabases and 98 references contributed by CAM experts; 170 
papers were included in the analysis. The review [6] concludes 
that in the scientific community there seems to be a consensus 
that the research methods used in conventional medicine are 
applicable to CAM. Randomised controlled trials are useful 
and applicable methods to evaluate CAM although in some 
circumstances it might be necessary to adapt these methods 
pragmatically. Furthermore, most authors are in favour of a 
broad integration of different research methods (a mixed 
methods approach), such as those used within comparative 
 effectiveness research (CER) and qualitative studies, to gather 
real-world evidence about CAM. Major issues described in the 
literature are the plethora of both general and specific prob-
lems experienced within CAM research and some thoughtful 
and specific suggestions on how to handle those in future re-
search. Interestingly, most problems are related to the design 
of clinical trials: patient selection, individualised treatments, 
randomisation and blinding. The probably most important and 
controversial discussion found in the literature seems to be the 
question whether efficacy or effectiveness research should be 
prioritised for future CAM research.
Based on this review, a workshop was held in Castellaro 
(Italy) September 7–9th 2011, with members of the CAMbrel-
la WP 7, representatives of CAMbrella’s advisory board and 
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health systems across countries. To overcome these problems, 
and in order to build a more solid foundation for future CAM 
research, new studies of CAM prevalence should consider the 
following strategies and suggestions to better enable data 
pooling and reporting accuracy:
– Identification of a core set of definitions of CAM practices 
and treatments in order to allow Europe-wide comparison 
of data. The understanding of what CAM actually is varies 
to a great extent between European countries. However, 
these definitions need to take national differences into 
account. 
– Development and agreement on a standardised method-
ology for surveys is essential for the comparison of the 
 collected data. This methodology should be based on good 
epidemiological practice, such as the STROBE criteria [7], 
and should include agreement on the relevant sociodemo-
graphic variables of interest.
– Observational studies are generally subject to various bias-
es. Since prevalence of use is a question which only can be 
answered through observational studies, researchers need 
to make efforts to manage various forms of bias, especially 
recall bias. Utilisation of representative samples and en-
couraging adequate response rates could help to manage 
self-selection bias and also enhance comparability.
– It would also be important to understand how CAM use 
differs between specific populations (healthy people and 
those with chronic illness) as we are aware that CAM is 
used mainly in addition to conventional care, but that its use 
is often not disclosed. This is potentially problematic be-
cause of interactions with conventional medications [8]; 
comparative studies between these different populations 
would be essential.
In conclusion, our suggestion is to develop a standardised 
approach towards prevalence research throughout Europe. 
We recommend: A Europe-wide approach to assess the 
prevalence of CAM use, practices and modalities using stan-
dard definitions.
Research Area 2: Needs and Attitudes of EU Citizens, 
Patients and Providers
Goal: To increase research-based knowledge about the 
availability of trustworthy information on CAM, access to 
CAM and quality of care in CAM for citizens, patients and 
providers in Europe.
Citizens’ attitudes and needs in relation to CAM have only 
been researched in 18 of the 39 countries in the EU with most 
of the research in the UK. This means that although some gen-
eral trends regarding access and quality of care can be identified 
across countries, this research-based knowledge does not cover 
the entire European region (see CAMbrella WP 3 report). 
A general need for easily accessible and trustworthy infor-
mation regarding CAM is essential. In some countries, citi-
zens’ personal social networks appear to constitute the main 
source of information about CAM, while biomedical profes-
sonal well-being; self-care approaches will become increas-
ingly important strategies by 2020 as we are developing more 
comorbidities in an ageing European population.
It is our aim to foster robust science that will have a major 
impact on public health, influencing the quality and quantity 
of life among the citizens of EU member states. We propose 
overall research fields of relevance and interest for all stake-
holders. We also suggest methodological strategies as to how 
those fields could be evaluated. 
The choice of research areas must be addressed strategi-
cally, in cooperation with conventional medical research 
groups (e.g., primary care, environmental medicine) and with 
the involvement of stakeholders, such as patients and medical 
and non-medical CAM providers.
We have identified 6 key research areas, crucial for develop-
ment of a broad, Europe-wide knowledge base for CAM by 
2020:
Research Area 1: CAM Prevalence in the EU
Goal: A valid descriptive overview of CAM use in Europe.
So far, knowledge about the prevalence of use of CAM in 
Europe is limited, and little information about CAM preva-
lence in Europe is available. Data across countries is inconsis-
tent, and it is currently impossible to compare the prevalence 
of CAM use across all EU member states. 
CAMbrella has reviewed the current scientific knowledge 
about the prevalence of CAM in Europe (see CAMbrella WP 
4 report). In our systematic review of CAM prevalence, 5,451 
studies were selected in an electronic search out of which 187 
papers were identified and analysed reporting the prevalence 
of CAM use in Europe. The main obstacles in prevalence re-
search were inconsistent or even absent definitions of CAM 
across the reports and concentration on country-specific CAM 
modalities. The methodology involved in the available epide-
miological studies was generally poor with many studies not 
piloting their data collection questionnaires and not reporting 
clearly about their population sample selection and the meth-
ods used to obtain a complete and representative sample. 
CAM use was often measured as a group of therapies rather 
than individually specified CAM modalities. Finally, because 
of the heterogeneity of the methods and definitions it was not 
possible to pool the data in a meta-analysis, and we cannot 
make a definitive statement of the CAM use in detail in Eu-
rope [6]. 
However, information about what is actually happening in 
Europe is vital to building a relevant research agenda. The 
lack of prevalence data is a major obstacle to conducting high 
quality research because it complicates and obscures the iden-
tification of the research fields that are relevant to citizens, 
providers and purchasers of CAM treatments. Given the di-
verse European situation with regard to legal regulation of 
provision and practice (see results of CAMbrella WP 2 re-
port), information about CAM prevalence is essential for 
health services research, especially the comparison of the 
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cations of current CAM education, training, certification and 
registration for clinical practice.
The major methodological deficiencies identified in rela-
tion to research about citizens’ needs and attitudes for CAM 
are:
– Most of the studies involve low quality reporting and hence 
uncertainty regarding the quality of the research methodol-
ogy and the veracity of their results. 
– Only few studies focus directly on citizens’ needs and 
attitudes. 
– There are a very limited number of articles reporting re-
search regarding citizens’ needs and attitudes in most of the 
EU countries. 
These deficiencies call for a strengthening of future re-
search in this area. Citizens’ attitudes and needs in relation to 
CAM deserve to be a priority. We need to obtain comparable 
and compatible data for all EU countries, so studies should be 
conducted in parallel in several EU countries where possible.
Research approaches suitable for addressing citizens’ atti-
tudes and needs include
– large-scale surveys based on validated questionnaires;
– qualitative interview and fieldwork studies with in-depth 
explorations of locally situated experiences and practice;
– interdisciplinary research, such as mixed methods studies, 
involving CAM providers and citizens as research partners. 
In general, research into citizens’ needs and attitudes needs 
to consider the local, regional and pan-European diversity of 
citizens (gender, age, ethnicity, social class) and the diversity of 
CAM provision, providers, practices and modalities.
We recommend: A programme of pan-European research 
identifying the citizens’ accessibility, preferences, reasons for 
use as well as reported effects and benefits for CAM. This 
should include the health economics of CAM as well as citi-
zens’ and CAM providers’ perspectives on education, training 
and practice of CAM provision. In doing so, attention should 
be paid to local traditions, ethnic minority groups and other 
sociocultural factors of relevance.
Research Area 3: CAM Safety
Goal: Gathering valid information about the safety and the 
risk/benefit of CAM treatments.
Based on the large number of people seeking CAM treat-
ment and the variability of provided CAM treatments, safety is 
an issue that must be addressed. Although CAM is considered 
to be largely safe by funders, citizens and providers, an evi-
dence base for this is essential for all stakeholders. 
Safety evaluations of CAM in the past have often focused 
on self-reports of serious adverse events as well as case re-
ports, without clarifying the quality of treatment, the popula-
tion denominators and potential causative mechanisms. There 
are at least 3 different domains, in which safety plays an impor-
tant role: CAM in the legislative area; the competency and 
safety of CAM providers and CAM therapies/products; and 
interactions between CAM and conventional medicine. 
sionals seem to constitute an important information source 
about CAM in other countries. In addition, but to a lesser ex-
tent, citizens seem to draw on print and broadcast media for 
information about CAM. Therefore, research-based knowl-
edge is needed about the validity of different sources of infor-
mation as the basis for citizens’ choice of treatment as well as 
the safe use and appropriateness of the chosen treatments.
The available research indicates that citizens generally wish 
to have easy access to CAM. A main obstacle in accessing 
CAM is that the user pays for treatment out-of-pocket in 
many countries. The literature points to 2 different attitudes in 
this regard: In countries where a substantial number of medi-
cal doctors provide CAM, citizens and patients seem to prefer 
that CAM provision be included in public health care. In coun-
tries such as UK and Denmark, where CAM is primarily pro-
vided by providers without a conventional medical back-
ground, citizens appear to be more reluctant to include CAM 
provision in public health care and seem to enjoy the relative 
freedom of choice of therapy this service model provides. 
There is a need for research that investigates citizens’ ac-
cess to and preferred models of CAM provision in Europe. 
This should include self-care and over-the-counter (OTC) use 
of CAM products as well as social and cultural aspects related 
to citizens’ needs and access to CAM for the various different 
models of CAM provision.
Research designed to help us understand citizens’ attitudes 
and needs concerning the quality of care in CAM provision 
and use indicates that citizens may value different and distinct 
aspects of CAM practice to other stakeholders. Issues men-
tioned in the literature as appealing to users include the pro-
vider-patient relationship and the associated greater involve-
ment in one’s own care; the individualised whole person 
approach frequently associated with CAM; and the explana-
tory frameworks for CAM that are congruent with the citi-
zens’ own ideas about health and illness, but may not be 
evidence-based. 
Therefore, research is needed into the relationship between 
the cultural assumptions underpinning CAM in different 
countries and their influence on the actual CAM practice with-
in diverse institutional settings. As part of this, it should be in-
vestigated whether the treatments include potentially health-
promoting involvement of patients. 
Another issue related to the quality of care concerns the 
qualifications and actual practice of the providers. The educa-
tional backgrounds for providers of CAM across and within 
countries, the forms of CAM and the institutional settings for 
CAM provision appear to be very heterogeneous as docu-
mented in the reports of WP 5 and WP 2. The implications of 
these findings for the educational qualifications of CAM prac-
titioners have not been investigated in a systematic manner. 
Thus, identification of the educational background and train-
ing of medical and non-medical CAM providers is needed. We 
need to understand why people decide to become CAM pro-
viders in the first place, and we need to understand the impli-
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Research Area 4: Comparative Effectiveness Research and 
Health Economic Evaluation
Goal: To support clinical and health care policy decision-
making by evaluating effectiveness and cost effectiveness. 
CER has considerable potential to help health care provid-
ers as well as patients and clinicians to generate evidence that 
will facilitate choice among currently available therapeutic op-
tions. According to the Institute of Medicine, CER is the gen-
eration and synthesis of evidence that compares the benefits 
and harms of alternative therapeutic methods to prevent, diag-
nose, treat and monitor a clinical condition or to improve the 
delivery of care. (Alternative does here not refer to ‘alterna-
tive medicine’, but to ‘best care’ options). The purpose of CER 
is to assist consumers, clinicians, purchasers and policy makers 
to make informed decisions that will improve health care for 
both the individual and population [9].
‘Efficacy’ refers to ‘the extent to which a specific interven-
tion is beneficial under ideal conditions’ [10]. By contrast, ‘ef-
fectiveness’ is a measure of the extent to which an interven-
tion, when deployed in routine circumstances, does what it is 
intended to do for a specific population [10]. Therefore, effec-
tiveness can often be more important and relevant to policy 
evaluation and the health care decisions of providers and pa-
tients than efficacy. The current movement in conventional 
medicine towards more CER places strong emphasis on the 
evaluation of different treatment options by including more 
heterogeneous patients and by using less standardised treat-
ment protocols and more patient-centred outcomes. However, 
to date, the majority of clinical trials on CAM have assessed 
the efficacy rather than the effectiveness. Unfortunately, ef-
forts to achieve methodological purity have often resulted in 
clinically meaningless and questionable results because pa-
tients, interventions and settings were not comparable to the 
real world; this meant the research outcomes were often not 
generalisable. CER plays an important role especially for 
CAM because, as opposed to conventional medicine, CAM is 
now widely available to the population. As a consequence, a 
reverse research strategy has been suggested for CAM, with 
the aim of establishing comparative effectiveness and safety 
before assessing efficacy of components [11, 12]. 
It is of major interest to ensure that future research on CAM 
reaches stakeholders to enable them to make informed deci-
sions in real-world situations. CER offers a wide range of re-
search designs [13] and advanced techniques to distil and con-
dense evidence from different types of studies. CER is not 
limited to randomised trials and includes, among other options, 
the possibility of using data from observational studies or regis-
tries. Pragmatic clinical trials are those randomised trials that are 
designed explicitly to meet the needs of clinical and policy deci-
sion making [14, 15]. When conducting pragmatic trials, one 
should take patients’ preferences regarding their therapy of 
choice into account, using either patient preference designs or 
documentation of patient preferences. Cluster-randomised trials 
are also a good option that could be used when appropriate.
CAM interventions often involve providing more or less 
complex treatment strategies to people (acupuncture, reflexol-
ogy and chiropractic). Safety of the people receiving these 
complex interventions must be secure. CAM treatments are 
often provided in combination with conventional medicine, 
e.g., pharmaceuticals. It is not clear if interactions between 
these treatments may occur which interfere with either the 
CAM or conventional intervention. Providing CAM treat-
ments must be safe and ethical for all CAM health care profes-
sionals including both medical and non-medical practitioners. 
A clear definition and taxonomy of safety in CAM is needed 
as prerequisite for valid research into CAM safety. It must 
take into account the availability of valid information about 
CAM treatments, treatment providers and the views of citi-
zens on safety of CAM.
The WP 3 literature review showed that citizens evaluate 
the safety of CAM relative to conventional medical treat-
ment, and often decide that CAM is safer than conventional 
medical treatment. Although it is known that conventional 
medical treatment can involve serious risks to the patient’s 
health, and the reported adverse effects of CAM in the re-
search literature are rarely of a serious nature, it is crucial to 
investigate this area more systematically using scientific com-
parisons of risks and benefits in different kinds of treatments 
and reporting and comparing risk/benefit ratios. Future safety 
evaluations should include information on the provided CAM 
treatment that was associated with the adverse event (often 
serendipitous associations, misdiagnosis, mistreatment or in-
sufficient treatment) and the interactions between CAM and 
conventional medicine.
In principle, 3 different types of safety documentation and 
research could be considered:
1. Europe- or country-wide CAM surveillance/register sys-
tems: Adverse effects associated with CAM should be docu-
mented; the most common as well as rare side effects should 
be covered. Ideally all people receiving CAM should be in-
cluded, so that proper denominators would be available to 
clarify potential risk.
2. Clinical trials, observational and comparative effective-
ness studies can be utilised to assess the risk of the more com-
mon side effects. This allows adequate comparison between 
benefit and risks of a given treatment compared to a defined 
control group such as usual care or standard treatment.
3. Single case studies and case histories: Very rare or excep-
tional adverse effect case histories should be documented and 
disseminated. Single case studies can be initiated in patients 
with an increased risk of side effects.
We recommend: Safety is a key issue for European citizens, 
and clear guidance on CAM safety is needed. A Europe-wide 
monitoring and registration system for clinical trials, observa-
tional and CER studies, single case studies and case histories 
should be implemented.
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Most CAM therapies are considered complex interven-
tions. Treatments sometimes cannot be reduced to a single 
specific therapeutic ingredient but may also encompass a spe-
cific setting as well as diagnostic and interaction processes 
[19]. Active or maybe only presumably active therapeutic in-
gredients are embedded in a contextual network. Further-
more we are frequently unsure about the underlying mecha-
nisms of some CAMs so that we may be unable to design an 
appropriate placebo intervention. Placebo research in the last 
2 decades has provided clear evidence that interventions 
without active ingredients can profoundly influence not only 
subjective perceptions but also physiological processes [20]. 
Such effects depend strongly on the meaning and context of 
an intervention and are mediated by a variety of mechanisms, 
such as expectation, conditioning and reward. While the con-
cept of complex interventions and experimental evidence 
from placebo research provides to some extent a theoretical 
rationale as to why CAM might be associated with strong 
meaning and context effects empirical, the evidence relevant 
to clinical practice is limited. 
Therefore we see a strong need for research that investi-
gates how and to what extent factors related to patients, pro-
viders, patient-provider relationship and interaction as well as 
to the setting in which CAM treatments are delivered influ-
ence patient-relevant outcomes. It is necessary to develop 
valid and reliable tools to assess components of meaning and 
context effects to facilitate research and allow for comparisons 
of results. Special emphasis should be placed on the question 
of whether CAM includes and provides meaning and context 
effects within the healing process in a different and broader 
context than conventional medicine. Such research could lead 
to a better understanding of the mechanisms of CAM, clarify 
the value of CAM for use by citizens and patients and help 
politicians when making reimbursement decisions. Under-
standing the mechanisms of meaning and contextual effects is 
also urgently needed to identify the appropriate scope and 
limits of CAM as well as conventional medical treatments. We 
are confident that deeper insights into the mechanisms of 
meaning and context effects will improve treatment in conven-
tional medicine, too.
For most CAM interventions the mechanisms of action are 
either unknown or only partly understood. Although the basic 
research on mechanisms of action is not part of this research 
roadmap it is fundamental to understand that more basic or 
experimental research is needed also in this field and that this 
needs to complement the research in meaning or context fac-
tors in CAM. Given the importance of context and meaning 
effects in all medicine, we believe that research into this area 
should be a priority for medical research in general. 
We recommend: Clinical research on CAM treatments 
should, whenever possible, include components that address 
aspects relevant to context and meaning effects and attempt to 
differentiate them from the intrinsic impact of any specific 
intervention. 
Within the framework of CER it is possible to address the 
most relevant issues regarding CAM in view of the upcoming 
health care challenges:
– Evaluating CAM as an optional add-on to conventional 
care as well as an alternative (best care) treatment strategy.
– Addressing medium and long-term effects of CAM in 
chronic diseases.
– Evaluating the cost/effectiveness ratio of a given CAM 
treatment compared to a defined control group (e.g., stan-
dard care, routine care).
– Involving stakeholders (such as citizens and patients, treat-
ment providers and health care managers/planners, hospital 
executives and others) in the design of CER studies and 
ensuring that research focuses on the evidence gaps most 
relevant to all health care decision makers [16].
Research in a real world-setting is the most promising and 
relevant approach to identifying the possible contribution of 
CAM to health care and health creation of European citizens.
We recommend: Future research should emphasize CER in 
CAM. This will create data that is valuable for all stakeholders 
and provide useful guidance for future research. Health eco-
nomic evaluation should be included within CER, and stake-
holders should be involved in all relevant stages.
Research Area 5: Meaning and Context Factors in CAM
Goal: To understand to what extent the clinical effects of 
CAM treatments are due to meaning and context effects and 
whether such effects differ from those in conventional 
medicine.
In most areas of CAM the majority of randomised clinical 
trials have investigated whether the intervention under test 
conditions has specific effects over a placebo or sham control 
intervention. While for a limited number of treatments such as 
St. John’s wort for depression [17], such specific effects have 
been shown beyond reasonable doubt, many trials have identi-
fied only small differences between real and placebo treat-
ments, and these have been of questionable clinical relevance. 
At the same time there is increasing evidence that patients 
benefit from a variety of CAM treatments compared to no 
treatment, usual care alone or in some cases even compared to 
guideline-based conventional care [18]. This raises some im-
portant questions: 
– To what extent CAM treatments work through the mecha-
nisms believed to be relevant by their proponents? 
– To what extent they work through meaning and context 
effects?
– Are they associated with stronger meaning or context ef-
fects than the conventional treatment option for some con-
ditions or some patients? 
These questions are not only of academic relevance. It 
could be that although a (CAM) therapy is not based on a 
valid theory or mechanism it may still be the most effective 
treatment option in a given situation. 
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ble decisions about CAM integration into health care, a valid 
description of the various models of how CAM is integrated is 
needed. These models should then be concurrently evaluated 
in order to identify their strengths and limitations. 
We recommend: A reliable description and concurrent eval-
uation of the existing models of CAM provision; the develop-
ment of innovative models of CAM provision in health care 
systems should be one focus of CAM research.
Methodological Considerations
There are some methodological and strategic considera-
tions which must be taken into account when formulating a 
research agenda in order to foster rigorous research in CAM. 
Over the last decade there has been a broad discussion 
about the utility of different research methods, and we have 
reviewed some of these important issues separately. We have 
identified several issues which have constrained the outcome 
of CAM research in the past, and we propose a methodologi-
cal framework to overcome these shortcomings. 
General Research Framework
Goal: To enhance the value of research by allowing a broad-
er and more complete assessment of the evidence.
From our point of view, an overall research framework for 
CAM needs to take the specific characteristics of CAM into 
account and include these in relation to any research design. 
Current trends in conventional medicine emphasise the fact 
that the implications of efficacy studies for clinical practice 
are overestimated. CER will better inform clinical decision- 
making in usual care, and standards for conducting patient-
centred research are currently developed [22]. 
We particularly favour multi-faceted, mixed method ap-
proaches for the evaluation of complex interventions, in which 
different methods are triangulated to gather the best available 
information using a non-hierarchical research approach. In 
quantitative studies, we prefer analyses which go beyond sole 
reliance on frequent statistics. The results of these statistics, 
such as effect sizes, numbers of subjects who respond and anal-
yses of individuals, need to be reported, in addition to the com-
monly accepted presentation of the primary outcomes, to 
 allow for a more inclusive interpretation of results. The 
 conduction of realist reviews [23] and reviews of research 
methods should allow comprehensive summaries of all types 
of research from different sources. Such syntheses should be 
prioritised in areas in which large numbers of individual stud-
ies already exist to provide information about best practices 
and to guide future research.
We recommend: Greater use of mixed methods approaches 
and more attention to the manner in which research results 
are transformed into coherent and conclusive reviews.
Research Area 6: Models of CAM Integration into the 
Health Systems
Goal: To research the different models for integration of 
CAM into health systems. 
There are a plethora of different CAM modalities and 
treatments, and there is a wide variety of ways in which CAM 
is provided to European citizens. For example, the legal 
 stat us and necessary qualifications for CAM provision differ 
between modalities and within European countries (see 
CAMbrella WP 2 report). This also affects the costs of CAM 
for European citizens. CAM is usually provided as an exclu-
sively private service often without any legal regulation, but 
in some cases there is regulation concerning the qualification 
of CAM providers and public provision of CAM (see 
CAMbrella WP 5 report). Some CAM modalities are sup-
ported and in some cases there is even reimbursement for 
CAM treatments provided by medical doctors or CAM 
practitioners within the public health care system. For exam-
ple, different approaches of CAM integration have been de-
scribed as ‘opposition’, ‘integration’ and ‘pluralism’ models 
[21]. A review of different models of CAM integration and 
their possible strengths and limitations in Europe is not yet 
available. CAM provision outside the medical system allows 
free choice of even ‘uncommon’ treatments and respects the 
freedom of European citizens as providers and users of 
CAM. On the other hand, this could affect safety and might 
undermine equity of access to treatment. Also, out-of-pocket 
expenditure for CAM treatments might not be affordable 
for some people or – in other cases – it might be cheaper 
than regular health care. Strong legal regulation might lead 
to the ‘underground’ provision of CAM without any quality 
control. 
Integration of CAM into the regular health service might 
enable citizens to access CAM more equitably and build ac-
ceptance for CAM, but could also limit the provision of CAM 
to selected techniques shown to be effective in treatment. This 
might weaken the possible beneficial effects, such as patient 
empowerment. These issues are complex and poorly under-
stood. CAM integration into health care is an individual and 
societal process of change which develops through the behav-
iours of patients, providers, stakeholders as well as evidence in 
different contexts of care. The implementation and provision 
of CAM is a complex matter that should be evaluated in detail 
as a complex intervention. ‘Integration’ doesn’t mean simply 
adding a certain amount of ‘unconventional’ to the ‘conven-
tional’ of routine care, but developing and testing models of 
integrated health care tailored to a patient’s needs, that in-
clude all conventional and CAM approaches that are appro-
priate. Ideally, an efficient integrative medicine model entails a 
coordinated, interactive and pragmatic process of change 
whose main participants are the health service workers and 
the attending patients.
At this stage there is no consensus as to which model of in-
tegration of CAM into the health care system is ideal. To ena-
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decision makers, and creating a comprehensive evidence base 
for CAM products and services.
Qualitative research methods are widely used in the field of 
social sciences, and they are increasingly acknowledged as vital 
to medical research. Qualitative research methods can increase 
knowledge about the perceived benefits or risks associated 
with CAM utilisation and provision, and often contribute a rich 
source of information complementing quantitative research. 
There are a number of different fields in which qualitative 
methods are important in CAM research:
– Exploring the philosophical contexts of CAM therapies 
and systems; 
– Investigating reasons and motives for utilisation or 
provision; 
– Exploring CAM treatment experiences including the pa-
tient-provider relationship. 
In addition, qualitative studies are crucial in informing 
quantitative research both when it comes to assessing the im-
pact of the interventions and interpretation of quantitative 
outcomes. Qualitative approaches are also helpful in structur-
ing the CAM research agenda and assisting in exploring the 
reasons for the heterogeneity of CAM regulation, financing, 
provision and utilisation in Europe. Qualitative methods are 
needed to broaden our knowledge base in CAM, particularly 
as we know too little about the multifaceted processes taking 
place in a CAM treatment. 
There is evidence from some countries (e.g., UK, Germany, 
France and Switzerland) of what citizens value about and 
within CAM (see CAMbrella WP 3 report), but we still do not 
know exactly what they value in CAM treatments for their in-
dividual complaints/diseases. We need to build a solid base of 
understanding in order to design research that helps to fill the 
gaps in key outcomes of the overall treatment process. Quali-
tative research and theory-building are needed to generate 
valid hypotheses and to support CER, and must therefore be 
integrated into any research strategy. While it is clear to us that 
many published qualitative CAM research articles are a rich 
source of patient-centred information, they tend to be small 
and narrowly focused. Meta-ethnography is a very suitable 
method for summarising knowledge from different qualitative 
sources, and could help to create deeper insight into the con-
ceptual models of CAM [33]. We consider that in addition to 
meta-analysis, meta-ethnography should also be part of the 
comprehensive evidence base for CAM. 
Qualitative methods can help to build the necessary knowl-
edge base, let us understand what happens in CAM treatments 
and what CAM practitioners understand they are doing. This 
helps us to understand the impact and patient perceptions of 
CAM. We fully support the increasing interest in combining 
qualitative and quantitative research methods to provide a 
comprehensive evidence base as well as the independent use 
of qualitative methods. The assessment of CAM treatments 
with qualitative studies is also very important to the prepara-
tion of clinical trials and to improve the study quality as well as 
Quantitative Research Methods
Goal: Accounting for complexities in CAM research 
through the use of quantitative research methods.
A substantial proportion of European populations utilise 
CAM in order to maintain and create health or treat their ill-
nesses [1, 24–26]. In order to enable European citizens, provid-
ers, policy makers and other stakeholders to arrive at informed 
decisions about CAM, they should have a reasonable degree 
of reliable information regarding
– use of CAM in Europe (see research area 1);
– attitudes towards the modality in question among Europe-
an citizens (see research area 3);
– safety of a specific modality or procedure and an under-
standing of its corresponding risks (see research area 2);
– level of acceptance among a group of providers and funders 
(see research area 3);
– effectiveness of a CAM modality in clinical practice (see 
research area 4);
– its economic sustainability (see research area 4).
In order to gather this information, different types of re-
search (effectiveness, safety, cost-effectiveness, citizens’ prefer-
ences and satisfaction, health services studies) are needed. 
Large-scale surveys can help to describe the attitudes of Euro-
pean citizens towards CAM and enable us to understand their 
knowledge, motivations and preferences with respect to CAM. 
Observational studies must be conducted to assess safety. Ran-
domised controlled trials in real-world settings are ideal to eval-
uate the effectiveness of a specific treatment or CAM modality 
in comparison to existing models of treatment, and concurrent 
observation of costs allows cost-effectiveness analysis. Different 
research questions call for different study designs, but these dif-
ferent types of quantitative studies are very relevant to allow us 
to answer these essential questions about CAM.
CAM modalities were conceived and developed in contexts 
very different from our present health services and often have 
a long history. Moreover, the different CAM modalities show 
different levels of complexity in their provision, varying from 
the simple prescription of a dietary supplement to the complex 
procedures involved in TCM, anthroposophic medicine, ho-
meopathy and other CAM medical systems. These need sub-
stantial knowledge regarding the procedures in question and, 
as a consequence, a careful and thoughtful adaption of re-
search methods. The available literature and ongoing discus-
sions already offer seminal and stimulating contributions with 
respect to the most suitable available research methods [27], 
conceptual frameworks [28, 29] and experiences [30–32].
We recommend: The adequate use and careful adaption 
of quantitative research methods to answer research ques- 
tions about CAM prevalence, safety, effectiveness and cost- 
effectiveness.
Qualitative Research in CAM
Goal: Gaining a deeper understanding about the opportu-
nities and challenges in CAM for consumers, providers and 
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Given this variability, a definitive EU-wide statement on which 
modalities should be primarily researched is impossible. 
Our overall view is that CAM modalities we should first 
evaluate should be those most likely to contribute the health 
research priorities within the EU. Criteria for the selection of 
CAM modalities for future research have been proposed in 
the literature (see WP 7 review), such as the prevalence of use, 
expected impact on clinical practice and the overall feasibility 
of conducting productive research in a specific area. These pri-
orities should be determined by a consensual process between 
the relevant stakeholders while taking into account the clinical 
and economic relevance of any research proposal.
We recommend: The choice of CAM modalities for which 
research is to be funded should be consensual and based on 
transparent criteria.
Research Infrastructure
Goal: Increase quality of CAM research by provision of op-
timal environments and a CAM research infrastructure in EU 
designed to foster collaboration and research excellence.
Good quality research which leads to thoughtful and in-
formed health care decision-making is our main objective. 
Currently there is little research on CAM in Europe and no 
structure through which research can be coordinated within 
the EU. There is almost no significant investment in any EU 
country in a CAM research structure or strategy. This is in 
stark contrast to the large CAM research initiatives found in 
USA, Asia and Australia. 
European CAM research suffers from
– a lack of knowledge about many of the CAM modalities, 
particularly if the research is carried out without the col-
laboration of CAM providers;
– poor collaboration with skilled conventional researchers 
and research structures; 
– poor research methodology within CAM; 
– limited and inadequate involvement of relevant 
stakeholders.
All these issues could and should be addressed by stake-
holders, such as research funders. Investment in research ca-
pacity and structure is vital to enable good quality research. 
There is an urgent need for sufficient independent CAM re-
search funding to 
– build research networks in Europe with the aim of harmo-
nising research nationally and internationally;
– attract experienced researchers to build research capacity 
in existing research groups that demonstrate metrics con-
sistent with research excellence;
– offer fellowships at junior research levels to build intellec-
tual capacity in high quality university departments com-
mitted to developing CAM research and collaborating with 
their conventional colleagues;
– develop structures that allow the dissemination of high 
quality reliable and trustworthy information about the evi-
dence for and against CAM. 
the treatment process. It helps to inform the selection of out-
come variables, to enable programme or process evaluation, to 
improve the researchers’ reflective process and to clarify the 
implications of quantitative results. 
We recommend: A stronger focus on qualitative research 
methods in order to provide syntheses and to explore the 
mechanisms and perceptions of CAM.
Stakeholder Involvement
Goal: Integration of all relevant perspectives and stake-
holder interests in the research agenda.
There are a number of stakeholders with varying and differ-
ent perspectives for whom CAM research is relevant. Among 
those are the European citizens as potential users of CAM, the 
various groups of medical and non-medical providers as well 
as policy makers and health care funders who define the con-
ceptual and legislative context for CAM provision. 
The integration of all these stakeholders’ views in the process 
of planning and designing as well as performing research is vital. 
Citizens and providers may have different views on the out-
comes they want to achieve with a specific CAM treatment. How 
a specific CAM modality or treatment is provided might vary 
significantly between different groups of providers. Obviously, 
the relevance and validity of CAM research depends to some 
extent on how these stakeholders’ views are taken into account.
Given the diverse pictures of CAM in Europe, these needs 
and attitudes have to be integrated into any research pro-
gramme in a structured manner. Qualitative methods, such as 
interviews and focus groups, as well as quantitative research 
methods, such as surveys, can be useful to assess the stakehold-
ers’ perspectives, ideas and interests. We believe that the qual-
ity and relevance of research will improve when stakeholders 
are integrated into the process of planning, conducting and 
 interpreting research.
We recommend: Structured and transparent stakeholder in-
volvement in all stages of CAM research is vital to ensure its 
relevance and validity.
CAM Modalities in the Research Areas
Goal: Research has to consider the possible contribution of 
CAM modalities to the EU health research priorities, therefore 
ensuring that the results are relevant for European citizens.
There is a wide range of different modalities within CAM. 
They all have different prevalence throughout Europe, hetero-
geneous evidence on efficacy and effectiveness as well as vari-
ous levels of private and publically funded practice. Their the-
oretical and historical backgrounds are diverse as are their 
‘assumed’ mechanisms of action. Definitions of CAM treat-
ments are not uniform throughout Europe (see CAMbrella 
WP 1). Our information on prevalence of use and acceptance 
by European populations (see results from CAMbrella 
WP 3–5) is too poor to be able to suggest any useful ranking of 
modalities as there are likely to be national or regional differ-
ences in the relative importance of different CAM modalities. 
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know far too little about the safety and effectiveness of many 
CAM treatments, their mechanisms of action and their possible 
cost/benefit ratio in clinical practice. Our vision for 2020 is to 
begin the creation of a sustainable, broad, relevant and compre-
hensive knowledge base which will allow informed decisions for 
citizens, providers, funders and political stakeholders on wheth-
er, when and how CAM should or could be utilised. 
We have identified several core research areas that need to 
be addressed urgently. Our current knowledge about which 
CAM modalities are used in Europe is incomplete. Europe-
wide consensual definitions for CAM and data collection iden-
tifying the commonly used CAM modalities are urgently 
needed. Safety is a major issue. Unlike drugs, CAM modalities 
have evolved over time in practice and most have not under-
gone any safety evaluation prior to use. While CAM treat-
ments may be safe, this needs to be properly investigated in 
order to protect European citizens.
We recommend the clinical evaluation of CAM from a real-
world perspective and, where appropriate, within a framework 
of CER. We believe that research into the effectiveness of 
CAM treatments within a real-world setting is the key to the 
clinically economically effective use of CAM within EU health 
care systems. We also suggest research that identifies the under-
lying specific effects of CAM, but consider that effectiveness 
research should be prioritised. We recommend developing a 
mechanism that enables the utilisation of all available research 
methods, including qualitative research, to investigate the theo-
retical foundations of CAM and to systematically aggregate 
knowledge from different studies. Given the probability of 
strong meaning and context effects throughout medical prac-
tice, these should also be addressed. 
Structural and sufficient financial support for research into 
CAM is urgently needed to develop the currently very limited 
research capacity. This could be achieved in the first step through 
the establishment of a European CAM coordinating research 
office and a time-limited grant to foster communication between 
EU governments, public, charitable and industry funders as well 
as researchers, citizens and other stakeholders. The aim of this 
office would be to develop a coordinated research strategy 
through existing research funding opportunities and to docu-
ment and disseminate international research activities in this 
field. In the long run, a European Centre for CAM (ECCAM) 
should be established to further develop coordinated research 
strategy for CAM with the capacity to award independent re-
search funding to foster high quality and robust research, with a 
focus on citizens’ health needs and pan-European collaboration. 
This would establish a collaborative research investment in 
CAM ultimately informing stakeholders in the EU about CAM 
and its use within EU health care systems. Our task is to ensure 
that treatments are safe for patients and that the use of CAM in 
clinical situations is based on the best evidence available.
In order to consider whether CAM could be a part of the 
solution to the health care, health creation and self-care chal-
lenges we face by 2020, it is vital to obtain a robust picture of 
This would enable the creation of a strong CAM research 
community establishing national and international research 
networks through the organisation and funding of annual 
meetings, conferences and research projects. Providing fellow-
ships and scholarships in the field will create the leaders of 
tomorrow and would help to both connect and develop cur-
rent European research capacity. 
Collaboration with international experts and CAM organisa-
tions, such as the International Society of Complementary Med-
icine Research (ISCMR) and the NCCAM, would foster the 
development of excellence within an EU research infrastruc-
ture for CAM. Within CAMbrella, we favour opportunities to 
facilitate communication among European CAM researchers 
(see CAMbrella WP 8 report) and to link our research capabili-
ties across Europe. In the past, no coordinated research strate-
gies have been available within the EU. In order to deploy the 
framework of CAM research as outlined in this research road-
map and to achieve a relevant impact of CAM research on peo-
ple’s health care in the future, there needs to be a an institu-
tional coordinated approach in research policy by the EU. We 
would suggest that as a first step, a European CAM research 
coordination office could be established that is dedicated to fos-
ter systematic communication between EU governments, pub-
lic, charitable and industry funders as well as researchers, citi-
zens and other stakeholders. The aim of this office would be to 
coordinate research strategy developments and research fund-
ing opportunities as well as to document and disseminate inter-
national research activities and their outcomes in particular 
clinical and epidemiological projects within the EU. This office 
would pursue a policy that is consistent with EU health creation 
policies and enable the development of CAM research through 
existing national and EU channels, such at the EU Framework 
Programme. This centre could also document and disseminate 
relevant EU and international CAM research projects. If this 
strategy is successful, then we suggest that this should develop 
into an EU-funded European Centre for CAM (ECCAM) 
comparable to the NCCAM in USA. The aim of such an Euro-
pean Centre for CAM would be to actively stimulate and sup-
port high quality research on CAM in the EU through an inde-
pendent research strategy, aligned with EU health policy and its 
own capacity for project and fellowship funding. 
We recommend: Improving the quality of CAM research by 
investing in education, training and collaboration of the CAM 
research community and by founding a European Centre for 
CAM (ECCAM) to stimulate high quality research in the EU. 
Conclusion
CAM is popular in Europe and utilised by a significant pro-
portion of EU citizens. Given the prevailing desire among citi-
zens for self-empowerment in relation to their health and the 
increasing number of ageing patients with chronic disease and 
comorbidity, a further increase in CAM use seems probable. We 
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CAM use and reliable information about its cost, safety and 
effectiveness in real-world settings. We need to consider how 
and in what ways CAM could be made available to European 
citizens. We need to engage in research excellence and utilise 
comparative effectiveness approaches, evidence syntheses and 
mixed methods to obtain this data. Our recommendations are 
both strategic and methodological. They are presented for the 
consideration of researchers and funders while being designed 
to answer the important and implicit questions posed by EU 
citizens currently using CAM. We propose an EU-funded Eu-
ropean Centre for CAM (ECCAM) research to foster high 
quality robust research based on pan-European collaboration. 
We wish to establish a solid foundation for CAM research to 
adequately inform health care and health decision-making 
throughout the EU. A European research centre would sup-
port our vision of a common, strategic and scientifically rigor-
ous approach to CAM research. We are confident that our rec-
ommendations will serve EU citizens.
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